Rosemary F. Kelly

Dr. Rosemary F. Kelly


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2004 in Chest
Verified
Journal Article
Closed access
RKRosemary F. Kelly
Rosemary F. Kelly
TTThao Tran
Thao Tran
AHAmy Holmstrom
Amy Holmstrom
JMJozef Murar
Jozef Murar
RSRomualdo J. Segurola
Romualdo J. Segurola

31 January 2011 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
RKRosemary F. Kelly
Rosemary F. Kelly
JCJesús A. Cabrera
Jesús A. Cabrera
EZElizabeth A. Ziemba
Elizabeth A. Ziemba
MCMelanie Crampton
Melanie Crampton
LALorraine B. Anderson
Lorraine B. Anderson
HWHerbert B. Ward
Herbert B. Ward

1 October 2005 in Chest
Verified
Journal Article
Closed access
PDF file
VSVita Sullivan
Vita Sullivan
TTTao Tran
Tao Tran
AHAmy Holmstrom
Amy Holmstrom
MKMichael Kuskowski
Michael Kuskowski
PKPaul Koh
Paul Koh
RKRosemary F. Kelly
Rosemary F. Kelly

4 November 2009 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
SMSalima Mithani
Salima Mithani
MAMuhammad S Akbar
Muhammad S Akbar
DJDeborah J Johnson
Deborah J Johnson
MKMichael Kuskowski
Michael Kuskowski
KAKatherine K Apple
Katherine K Apple
SASelcuk Adabag
Selcuk Adabag
Previous studies on the effects of Statins in preventing atrial fibrillation (AF) after cardiac surgery have shown conflicting results. Whether statins prevent AF in patients treated with postoperative beta blockers and whether the statin-effect is dose related are unknown.

31 October 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
RARishav Aggarwal
Rishav Aggarwal
KPKoray Niels Potel
Koray Niels Potel
EMedward mcfalls
edward mcfalls
Tammy A ButterickTammy A Butterick
Tammy A Butterick
RKRosemary F. Kelly
Rosemary F. Kelly
Ischemic heart disease affects millions of people around the world. Current treatment options, including coronary artery bypass grafting, do not result in full functional recovery, highlighting the need for novel adjunctive therapeutic approaches. Hibernation describes the myocardial response to prolonged ischemia and involves a set of complex cytoprotective metabolic and functional adaptations. PGC1-alpha, a key regulator of mitochondrial energy metabolism and inhibitor of oxidant-stress-inflammatory signaling, is known to be downregulated in hibernating myocardium. PGC1-alpha is a critical component of cellular stress responses and links cellular metabolism with inflammation in the ischemic heart. While beneficial in the acute setting, a chronic state of hibernation can be associated with self-perpetuating oxidant stress-inflammatory signaling which leads to tissue injury. It is likely that incomplete functional recovery following revascularization of chronically ischemic myocardium is due to persistence of metabolic changes as well as prooxidant and proinflammatory signaling. Enhancement of PGC1-alpha signaling has been proposed as a possible way to improve functional recovery in patients with ischemic heart disease. Adjunctive mesenchymal stem cell therapy has been shown to induce PGC1-alpha signaling in hibernating myocardium and could help improve clinical outcomes for patients undergoing bypass surgery.

1 January 2015 in Journal of Surgical Research
Verified
Journal Article
Closed access
CHChristopher T. Holley
Christopher T. Holley
CDCayla M. Duffy
Cayla M. Duffy
TBTammy A. Butterick
Tammy A. Butterick
ELEric K. Long
Eric K. Long
MLMegan E. Lindsey
Megan E. Lindsey
RKRosemary F. Kelly
Rosemary F. Kelly